STRUCTURAL BASIS OF CD59 AND CD58 SIGNALING TO T CELLS
CD59 和 CD58 向 T 细胞发出信号的结构基础
基本信息
- 批准号:6343532
- 负责人:
- 金额:$ 32.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-01-01 至 2002-12-31
- 项目状态:已结题
- 来源:
- 关键词:3T3 cells CD antigens CHO cells SCID mouse T lymphocyte anergy antigen antibody reaction antigen presenting cell cell adhesion molecules cell cell interaction histocompatibility human subject leukocyte adhesion molecules phlebotomy protein structure function tissue /cell culture transfection transplantation immunology vascular endothelium xenotransplantation
项目摘要
DESCRIPTION (Adapted from the Applicant's Abstract): This is a competitive
renewal application. The goals of this project are to characterize specific
costimulatory pathways invoked during allo and xeno immune responses to
endothelium. Studies have defined common properties of the responses to
human and porcine ECs but also have identified a major important difference
regarding the expression of B7. There are substantial sequence differences
in the cell surface antigens between these antigens and their contribution
to signaling via ligand interactions may differ significantly.
The response of human T cells is much stronger to porcine ECs than human
allogeneic ECs. This is a consequence of direct recognition of MHC class I
and class II antigens as well as the presence of pB7.2 on porcine ECs. The
role of CD58 and CD59 in the CD2 pathway and pB7.2 in the CD28 pathway in
xeno responses will be studied. The activation of human T cells will be
assessed using complementary approaches.
The contribution of distinct ligand interactions on transfected CHO cells
individually or in combination will be examined. This will include normal
and mutant forms of human CD58 and CD59 antigens as well as normal forms of
these homologous porcine antigens. In addition, more complex antigen
presenting cells will be studied after removing defined antigens. Several
strategies will be employed to specifically inhibit the cell surface
expression of SLA antigens and costimulatory molecules (pB7.2, CD59, CD58)
on human and porcine ECs. Both primary as well as recall responses will be
evaluated.
The ability of human T cells to recognize SLA antigens will be studied by
expressing these antigens on transfected cells. Recognition of SLA antigens
in the absence of a costimulatory signal may result in induction of anergic
human T cells. Transfections of NIH3T3 cells with SLA antigens plus
additional costimulatory molecules will be utilized to define the
requirements for breaking anergy. Comparisons between human and porcine
systems will be made in order to define the critical pathways that could be
targets for facilitating tissue transplants. Finally, the applicants will
utilize an in vivo model in which the immune system of SCID mice has been
reconstituted with human cells. The immunogenic properties of the
transfected porcine ECs that have demonstrated altered recognition
properties in culture will be evaluated in this model after formation of
synthetic vascular networks in collagen gels.
描述(改编自申请者摘要):这是一份竞争性的
续签申请。这个项目的目标是描述特定的
在异种和异种免疫应答过程中激活的共刺激通路
内皮细胞。研究已经确定了对以下各项反应的共同属性
人类和猪的ECs也发现了一个重大的重要区别
关于B7的表达。有很大的序列差异
在细胞表面抗原之间的这些抗原和它们的贡献
通过配基相互作用发出的信号可能有很大的不同。
人T细胞对猪内皮细胞的反应比人强得多
异体血管内皮细胞。这是直接承认MHC I类的结果
和II类抗原,以及猪内皮细胞上pB7.2的存在。这个
CD58、CD59在CD2通路中的作用及pB7.2在CD28通路中的作用
我们将研究Xeno的响应。人类T细胞的激活将是
使用补充办法进行评估。
不同配体相互作用对转基因CHO细胞的贡献
将单独或结合进行检查。这将包括正常
和人类CD58和CD59抗原的突变形式以及正常形式的
这些同源的猪抗原。此外,更复杂的抗原
在去除确定的抗原后,将对呈递细胞进行研究。几个
将采用特定的策略来抑制细胞表面
SLA抗原和共刺激分子(pB7.2、CD59、CD58)的表达
在人和猪的内皮细胞上。主要和召回响应都将是
已评估。
人类T细胞识别SLA抗原的能力将通过以下方法进行研究
在转基因细胞上表达这些抗原。SLA抗原的识别
在没有共刺激信号的情况下可能会导致诱发无能
人类T细胞。SLA抗原Plus基因导入NIH3T3细胞的研究
其他的共刺激分子将被用来定义
打破无能为力的要求。人与猪的比较
将建立系统,以定义可能是
促进组织移植的目标。最后,申请者将
利用体内模型,其中SCID小鼠的免疫系统已经
用人类细胞重组。猪瘟病毒的免疫原性
表现出识别能力改变的转基因猪内皮细胞
在此模型中将在形成后评估培养中的特性
胶原蛋白凝胶中的合成血管网络。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALFRED LM BOTHWELL其他文献
ALFRED LM BOTHWELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALFRED LM BOTHWELL', 18)}}的其他基金
Revascularization of Islets to Treat Type I Diabetes
胰岛血运重建治疗 I 型糖尿病
- 批准号:
7209702 - 财政年份:2007
- 资助金额:
$ 32.45万 - 项目类别:
Regulation of Cell survival Following T Cell Recognition
T 细胞识别后细胞存活的调节
- 批准号:
6906582 - 财政年份:1997
- 资助金额:
$ 32.45万 - 项目类别:
相似海外基金
Analysis of expression of Cd antigens in retinoblastoma, and its application for disease classification and therapeutic strategy
视网膜母细胞瘤中Cd抗原的表达分析及其在疾病分类和治疗策略中的应用
- 批准号:
25670726 - 财政年份:2013
- 资助金额:
$ 32.45万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research














{{item.name}}会员




